Commerce and Industry Minister Piyush Goyal on Monday, 2 November 2026, convened a meeting with India's biopharma and biotechnology startups in New Delhi to identify key growth bottlenecks and chart a path for accelerating the sector. The discussions focused on simplifying regulatory processes, improving access to capital, expediting patent approvals, and strengthening indigenous procurement and research infrastructure.

What the Government Said

Minister Goyal signalled that coordinated inter-ministerial action is under consideration to address structural constraints facing biopharma startups. 'Stronger collaboration between government, industry and research institutions will help innovative startups scale and contribute to India's growing bioeconomy,' he said during the session.

He also highlighted the role of the Biotechnology Industry Research Assistance Council (BIRAC) in building shared infrastructure — including bio foundries, Bio-AI hubs, and advanced biomanufacturing platforms — as part of the government's broader transformation agenda.

India's Bioeconomy by the Numbers

According to the India BioEconomy Report (IBER) 2026, India's bioeconomy has grown from approximately $10 billion in 2014 to over $195 billion in 2025, recording a compound annual growth rate (CAGR) of nearly 18%. The sector contributes around 4.8% to national GDP and is supported by over 11,800 biotech startups across the country.

The sector has more than doubled in size since 2020, and annual growth in the last year alone stood at 17–18%, rising from approximately $165 billion to $195 billion. India is now targeting a $300 billion bioeconomy by 2030.

Key Policy Levers: BioE3 and the RDI Fund

The Centre's BioE3 Policy — Biotechnology for Economy, Environment, and Employment — is designed to promote innovation in precision biotherapeutics, smart proteins, climate-resilient agriculture, bio-based chemicals, and carbon capture technologies. This policy provides a regulatory and incentive architecture aimed at scaling sustainable biomanufacturing.

Separately, the government has established a Research, Development, and Innovation (RDI) Fund with an outlay of ₹1 lakh crore, under which BIRAC has been assigned a lead role in channelling long-term investment into projects ready for scale-up and technology translation. The fund is intended to deepen India's deep-tech ecosystem.

What It Means for Startups and the Sector

With over 11,800 biotech startups already operational, the immediate priority, according to reports from the meeting, is reducing time-to-market through faster patent approvals and smoother regulatory clearances. Analysts have noted that India's biopharma startup ecosystem remains underfunded relative to its scientific talent base, making the RDI Fund's scale significant.

This comes amid a broader global reorientation toward bio-based economies, with the United States, the European Union, and China each ramping up biomanufacturing investment. India's push, if executed effectively, could position it as a preferred destination for contract biomanufacturing and drug discovery partnerships.

What Comes Next

No specific timelines were announced for regulatory reforms following Monday's discussions, but the government has indicated that actionable proposals will emerge from ongoing consultations between industry, research institutions, and the ministry. Industry observers will be watching for formal policy notifications under the BioE3 framework and the first disbursement tranches from the RDI Fund in the coming months.